Trial Profile

A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ziftomenib (Primary) ; Cytarabine; Daunorubicin
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man; Registrational; Therapeutic Use
Acronyms KOMET-001
Sponsors Kura Oncology

Most Recent Events

18 Jun 2025 The protocol has been amended to addition in treatment arm and size and addition in safety and efficacy Primary endpoints.
18 Jun 2025 Planned number of patients changed from 85 to 263.
02 Jun 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com